Your session is about to expire
← Back to Search
Atorvastatin for Heart Failure in Patients Receiving Anthracycline (SPARE-HF Trial)
SPARE-HF Trial Summary
This trial will test whether statins can prevent heart failure from anthracycline chemotherapy.
- Cardiotoxicity
- Heart Failure
- Cancer
SPARE-HF Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSPARE-HF Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2014 Phase 3 trial • 58 Patients • NCT02084069SPARE-HF Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have a serious problem with one of your heart valves causing it to be too narrow or leaky.You had a bad reaction to statin medication before.You are already taking statin medication or have a condition that requires statin treatment.Your creatine kinase (CK) level is more than three times the upper limit of normal.Your liver is not working properly, as shown by a certain blood test being higher than normal.You are taking a strong medication that affects how your body processes other drugs.You are expected to live for less than a year.You cannot have a cardiac MRI if you have a pacemaker, ICD, or other metal objects in your body that are not safe for an MRI, or if your kidney function is severely impaired.You have a high risk for heart problems based on certain criteria.You have a history of hypothyroidism that is not well controlled.Your creatinine levels are higher than 177 micromoles per liter.You have certain types of cancer that need treatment with a specific type of chemotherapy called anthracycline for a chance to cure the cancer.
- Group 1: Placebos
- Group 2: Statin
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has Atorvastatin been cleared by the FDA?
"While there is some data suggesting that Atorvastatin is safe, it is still in Phase 2 of clinical trials and has yet to be proven effective. Therefore, it received a score of 2."
What issues has Atorvastatin been effective in treating in the past?
"Atorvastatin has been shown to decrease postoperative thromboembolism, anginal pain, and lipidemias."
How many people are included as test subjects in this research?
"At the moment, this trial is not looking for any more participants. The trial was first posted on May 10th, 2018 and was last updated on February 4th, 2022. There are 1239 other studies that are actively recruiting patients with malignancies and 73 studies for Atorvastatin that are actively recruiting patients."
Are there any more spots open for people who want to join this research project?
"Unfortunately, this particular clinical trial is not currently enrolling patients. The listing was first posted on May 10th, 2018 and was last edited on February 4th, 2022. However, there are 1239 other clinical trials for patients with malignancies and 73 trials for Atorvastatin that are actively recruiting patients."
Does this type of clinical trial exist anywhere else in the world?
"Merck Sharp & Dohme LLC sponsored the first study of Atorvastatin in 2005, which involved 80 patients and completed Phase 4 drug approval. Since then, 527 studies have been conducted in 28 countries and 162 cities."
Share this study with friends
Copy Link
Messenger